A retrovirus homologue gene of cellular cyclin D1, walleye dermal sarcoma virus rv-cyclin gene (orf A or rv-cyclin), was expressed in the livers of zebrafish under the control of liver fatty-acid binding protein (lfabp) promoter. To prevent possible fatality caused by over-expression of the oncogene, the GAL4/UAS system was used to maintain the transgenic lines. Thus, both GAL4-activator, Tg(lfabp:GAL4), and UAS-effector, Tg(UAS:rvcyclin), lines were generated and the rv-cyclin gene was activated in the liver after crossing these two lines. Since no obvious neoplasial phenotypes were observed in the double-transgenic line, cancer susceptibility of the transgenic fish expressing rv-cyclin was tested by carcinogen treatment. Unexpectedly, transgenic fish expressing rv-cyclin gene (rvcyclin+) seemed to be more resistant to the carcinogen than were siblings not expressing this gene (rvcyclin−). Lower incidences of multiple and malignant liver tumors were observed in rvcyclin+ than in rvcyclin− fish, and the liver tumors in the rvcyclin+ group appeared later and less severe. These results suggest that expression of rv-cyclin protects the fish liver from carcinogen damage and delays onset of malignancy. This observation—from a transgenic fish model—may be relevant to studies of liver-cancer inhibition and regression.